Venture Fund Member Profile
|
 |
 |
Paladin Capital Group is an established, multi-stage private equity firm that invests in growing worker-friendly companies through acquisitions and expansion capital. Headquartered in Washington D.C., Paladin has approximately half a billion dollars under management across two distinct funds. The firm’s leadership is comprised of individuals with a proven track record of financial expertise, national security experience and specialized technical competence. Collectively, Paladin’s Principals have completed over 100 direct and co-investments in a wide range of industries, including: IT Services, Mesh Networks, Data Storage, Business Process Software, Network Management software, Detection, Biometrics, Search Software, Electronic/Network Hardware, Alternative Energy & Clean Energy Technologies, Network Security, Communications Interoperability & Reconstruction, Biological/Chemical/Radiological Remediation, Protective Equipment, Asset Tracking & Container Security, Industrial Manufacturing, Educational Services, Energy/Environment, Healthcare Services and Financial Services.
 |
William Reinisch
Venture Advisor
Paladin Capital Group |
William Reinisch is responsible for the investment activities in the New York office of Paladin Capital. He is also the CEO and Founder of XIV River. He specializes in strategy and investments for the high tech industry. He is currently an Adjunct Professor at Stevens Institute of Technology. He was most previously the Vice President of Strategy and Technology with Motorola. In this role he was responsible for intellectual property standards and the corporate technology portfolio in addition to positioning Motorola for growth in emerging new market segments. Previously, he was Vice President of strategy and new initiatives and joined Motorola as a strategic advisor to the Chief Strategy Office. Prior to joining Motorola he was Senior Vice President of operations and engineering at Magnolia Broadband, where he led engineering and operations for the company. Before that, he led the global technology organization at Multilink Technology Corporation, a company focused on high-speed solutions for advanced optical networks. He has authored several publications, presentations, three US patents and several patent applications. He earned an MBA from Fordham University and a B.S. from Rochester Institute of Technology (R.I.T.). As a native New Yorker, William is uniquely positioned to assist rapidly growing technology companies in the New York Market.
Representative Investments
 |
Application Security is a leading provider of database security solutions for the enterprise. AppSecInc products proactively secure enterprise applications at more than 400 organizations around the world by discovering, assessing, and protecting the database against rapidly changing security threats. By securing data at its source, AppSecInc enables organizations to more confidently extend their business with customers, partners and suppliers. The company’s security experts, combined with its strong support team, deliver up-to-date application safeguards that minimize risk and eliminate its impact on business. |
 |
BA Insight provides a product that enhances the capability of existing enterprise search platforms such as Microsoft’s Sharepoint, expanding the data sources available to them and improving the way users interact with the results. The Company’s core product is named Longitude. Longitude has two primary functions – allowing users to preview the contents of documents without downloading them and using the users’ interactions with those documents to enhance the results of future searches. |
 |
Orchestria Leading provider of software assuring compliance with all forms of regulatory and business policy as they relate to electronic communications. Orchestria was acquired by CA in December of 2008.
|
 |
Royalty Pharma invests in pharmaceutical and biotechnology product royalties and other revenue-producing intellectual property. Royalty Pharma currently owns a diversified portfolio of royalties in 22 products: 16 leading approved and marketed pharmaceutical and pharmaceutical products, 5 products in Phase II clinical trials and/or under review with the FDA and one product in early stage of clinical development. The development of critical care treatments, therapies and vaccines for life-threatening diseases, viruses and other ailments form on of the cornerstones of the “cope” and “recover” aspects of Paladin’s homeland security investment strategy. Royalty Pharma could potentially use Paladin’s investment funds to acquire interests in other treatments for various epidemic/pandemic diseases including those that could intentionally be used for bioterrorism. Neupogen/Neulasta, one of the largest products in Royalty Pharma’s current collection is a critical key medical countermeasure in the nation’s defense against terrorism in the event of a nuclear or radiological attack, such as a dirty bomb. Importantly, the drug has been granted special approval by the FDA for deployment in the event of an emergency. Accordingly, the product is a vital tool in the defense of the nation, and is the only treatment currently held inthe Strategic National Stockpile for treating Acute Radiation Sickness in the event of a mass casualty event. |
William participated in the FundingPost event: NYC VC & Angel Showcase
on Thursday, February 7, 2013 in NY, Sponsored by Credit Suisse, WeiserMazars, SocialRadius, Greenberg Traurig, Office Lease Center
To list your Company on our website and make your profile available to William and 7,500+ other VCs and Angel Investors, Click Here.
============================================
About FundingPost
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
============================================
|
| Venture Fund Member Profile |
|
Bookmark to del.icio.us
Tweet this Profile
